9 results on '"Sandhu, Karamjeet"'
Search Results
2. Treatment of relapsed or refractory FLT-3 acute myelogenous leukemia with a triplet regimen of hypomethylating agent, venetoclax, and gilteritinib.
- Author
-
Ngo, Dat, Tinajero, Jose, Li, Shanpeng, Palmer, Joycelynne, Pourhassan, Hoda, Aribi, Ahmed, Nakamura, Ryotaro, Stein, Anthony, Marcucci, Guido, Salhotra, Amandeep, Sandhu, Karamjeet, Pullarkat, Vinod, Ball, Brian, and Koller, Paul
- Subjects
ACUTE myeloid leukemia ,VENETOCLAX ,HEMATOPOIETIC stem cells ,STEM cell transplantation ,PROTEIN-tyrosine kinases - Abstract
Relapsed or refractory (R/R) acute myeloid leukemia (AML) with FMS-like tyrosine kinase 3 (FLT3) mutations remains a difficult and hard to treat entity. Gilteritinib is a potent oral FLT-3 inhibitor that improves overall survival in R/R AML, but studies are limited in combining gilteritinib with a hypomethylating agent and venetoclax treatment backbone (HMA-VEN-GILT). Here we report our experience with HMA-VEN-GILT for 22 R/R FLT3 AML patients. HMA-VEN-GILT yielded an ORR of 77.3% (17/22), CR 4.5% (1/22), CRi 13.6% (3/22), MLFS 59.1% (13/22). Median follow-up was 10.4 months with a relapse rate of 29.4% (5/17), median time to relapse of 69 days (range 35–298 days), 6-month overall survival of 84%, and median OS of 10.1 months. Additionally, 36.4% (8/22) of patients proceeded to hematopoietic stem cell transplant. In conclusion, HMA-VEN-GILT for the treatment of R/R FLT3 AML is feasible and can be used as a bridge to allogeneic transplantation. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. WT1-mutated acute myeloid leukemia is sensitive to fludarabine-based chemotherapy and conditioning regimens.
- Author
-
Aribi, Ahmed, Salhotra, Amandeep, Afkhami, Michelle, Munteanu, Anamaria, Ali, Haris, Aldoss, Ibrahim, Otoukesh, Salman, Al Malki, Monzr M., Sandhu, Karamjeet S., Koller, Paul, Arslan, Shukaib, Stewart, Forrest, Artz, Andrew, Curtin, Peter, Ball, Brian, O'Hearn, James, Spielberger, Ricardo, Smith, Eileen, Budde, Elizabeth, and Nakamura, Ryotaro
- Subjects
ACUTE myeloid leukemia ,STEM cell transplantation ,CANCER chemotherapy ,FLUDARABINE - Abstract
We conducted a retrospective analysis of WT1-mutated acute myeloid leukemia (AML) patients who underwent allogeneic stem cell transplant. Thirty-seven patients with WT1-mutated AML were identified. Primary induction failure (40%) and early relapse rate (18%) after idarubicin/cytarabine (7 + 3) chemotherapy were observed. All patients with induction failure subsequently achieved CR with additional chemotherapy. There was no significant difference between outcomes after myeloablative vs. reduced intensity (Fludarabine/Melphalan [Flu/Mel]) conditioning regimens. RFS but not OS was significantly better in patients who received FLAG-IDA prior to transplant and/or a fludarabine-containing conditioning. In an independent ex vivo study, WT1-mutated AML samples exhibited greater sensitivity to fludarabine (p = 0.026) and melphalan (p = 0.0005) than non-WT1-mutated AML samples while there was no difference between sensitivity to cytarabine. Our data favor using a fludarabine-based induction for AML with WT1 mutation instead of 7 + 3. Fludarabine conditioning regimens for alloHCT showed better RFS but not OS. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. Clinical experience with venetoclax and hypomethylating agents (HMA) in patients with newly diagnosed and relapsed or refractory KMT2A-Rearranged acute myeloid leukemia (AML).
- Author
-
Ball, Brian J., Arslan, Shukaib, Koller, Paul, Ngo, Dat, Afkhami, Michelle, Salhotra, Amandeep, Al-Malki, Monzr, Aribi, Ahmed, Ali, Haris, Sandhu, Karamjeet, Otoukesh, Salman, Amanam, Idoroenyi, Pourhassan, Hoda, Artz, Andrew, Curtin, Peter, Stein, Anthony, Nakamura, Ryotaro, Marcucci, Guido, Smith, Eileen, and Pullarkat, Vinod
- Subjects
ACUTE myeloid leukemia ,VENETOCLAX - Abstract
Rearrangements of I lysine [K] methyltransferase 2 A i ( I KMT2A i ) gene, previously known as the I MLL i gene, occur in 3 to 7% of adult patients with de novo AML and are enriched in therapy-related disease, particularly after treatment with topoisomerase II inhibitors [[1]]. Response and survival of patients with KMT2A rearranged acute myeloid leukemia (AML) receiving venetoclax in combination with hypomethylating agent therapy (HMA). The inferior prognosis of KMT2A rearranged AML patients undergoing alloSCT presents an opportunity for post-transplant maintenance trials with therapies targeting KMT2A. [Extracted from the article]
- Published
- 2022
- Full Text
- View/download PDF
5. Venetoclax and hypomethylating agents yield high response rates and favourable transplant outcomes in patients with newly diagnosed acute myeloid leukaemia.
- Author
-
Salhotra, Amandeep, Tsai, Ni‐Chun, Zhang, Jianying, Ngo, Dat, Aribi, Ahmed, Sandhu, Karamjeet, Ball, Brian, Al‐Malki, Monzr, Ali, Haris, Koller, Paul, Artz, Andrew, Forman, Stephen, Nakamura, Ryotaro, Stein, Anthony, Marcucci, Guido, Aldoss, Ibrahim, and Pullarkat, Vinod
- Subjects
ACUTE myeloid leukemia ,CHRONIC leukemia ,TREATMENT effectiveness ,VENETOCLAX - Abstract
The 1-year OS for HCT patients (21 patients) was 85% (95% CI 61-95%) compared to 41% (95% CI 16-65%) in non-HCT patients in cCR (14 patients). The 1-year LFS in patients who underwent HCT (21 patients) was 67% (95% CI 41-84%) I versus i 33% (95% CI 10-57%) in non-HCT patients in cCR (14 patients). [Extracted from the article]
- Published
- 2022
- Full Text
- View/download PDF
6. Outcome of Allogeneic Hematopoietic Cell Transplantation after Venetoclax and Hypomethylating Agent Therapy for Acute Myelogenous Leukemia.
- Author
-
Sandhu, Karamjeet S., Dadwal, Sanjeet, Yang, Dongyun, Mei, Matthew, Palmer, Joycelynne, Salhotra, Amandeep, Al Malki, Monzr, Aribi, Ahmed, Ali, Haris, Khaled, Samer, Forman, Stephen J., Snyder, David, Nakamura, Ryotaro, Stein, Anthony S., Marcucci, Guido, Aldoss, Ibrahim, and Pullarkat, Vinod
- Subjects
- *
ACUTE myeloid leukemia , *CELL transplantation , *OLDER patients , *GRAFT versus host disease , *PROGRESSION-free survival - Abstract
• The combination of hypomethylating agents with the selective Bcl-2 inhibitor venetoclax (VEN-HMA) as a bridge to allogeneic hematopoietic cell transplantation (alloHCT) is associated with favorable HCT outcomes. • VEN-HMA could allow more patients of older age to proceed to potentially curative alloHCT. • AlloHCT outcomes are particularly good in patients who undergo HCT in complete remission after VEN-HMA therapy. The combination of hypomethylating agents with the selective Bcl-2 inhibitor venetoclax (HMA-VEN) has emerged as a highly active regimen in patients with acute myelogenous leukemia (AML) in both the upfront and relapsed/refractory (r/r) settings. We report our early experience with a cohort of patients who were able to proceed to allogeneic hematopoietic cell transplantation (alloHCT) after HMA-VEN therapy. Thirty-two patients with AML (19 r/r and 13 de novo) with a median age of 62 years underwent alloHCT after HMA-VEN therapy. Twenty-two (68.8%) were in complete remission (CR)/CR with incomplete count recovery at time of HCT. With a median follow up of 14.4 months, the 1-year overall survival (OS) was 62.5%, and disease-free survival was 43.8%. The 1-year nonrelapse mortality rate was 18.8%, and the cumulative incidence of relapse was 37.5%. Among patients who underwent alloHCT in CR, the 1-year OS was 77.3%, and the cumulative incidence of nonrelapse mortality was 9.1%. The cumulative incidence of grade II-IV acute graft-versus-host disease was 43.8%. We conclude that alloHCT after HMA-VEN is therapy associated with favorable allogeneic HCT outcomes in newly diagnosed older patients with AML, as well as those with r/r AML. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
7. Concurrent versus sequential or no triazole anti-fungal therapy in patients undergoing 7 + 3 plus midostaurin induction for FLT-3 acute myelogenous leukemia.
- Author
-
Ngo, Dat, Tinajero, Jose, Zhang, Jianying, Stein, Anthony, Marcucci, Guido, Salhotra, Amandeep, Pullarkat, Vinod, Sandhu, Karamjeet S, Ball, Brian J, Pourhassan, Hoda, and Koller, Paul
- Subjects
- *
ACUTE myeloid leukemia , *PROTEIN-tyrosine kinases , *MYCOSES , *ANTINEOPLASTIC agents , *CYTOCHROME P-450 CYP3A - Abstract
Midostaurin is a multikinase inhibitor approved for the treatment of adult patients with newly diagnosed FMS-like tyrosine kinase 3 mutated (FLT3m) acute myeloid leukemia (AML). Azole antifungal medications are commonly used in AML and are known to interact with anti-cancer drugs such as midostaurin through the CYP3A pathway. However, there are no midostaurin related dose modifications recommended with strong CYP3A inhibitors.We retrospectively reviewed 40 patients between 2017–2022 and compared efficacy and safety outcomes in patients who received azole antifungals concurrently to those who did not receive an azole or received it sequentially to midostaurin for treatment of FLT3m AML.Median age of both groups was approximately 55 years and 70% of patients harbored FLT-3 internal tandem duplication mutations. Most patients in the concurrent arm were on either posaconazole (33%) or isavuconazole (50%) for antifungal prophylaxis and micafungin (72%) for the sequential/no azole arm. Overall CR/CRi rate with concurrent versus sequential/no azole were 72% and 77%, and non-hematologic grade 3 toxicities were 22% and 40% (
p = 0.21), respectively. Rates of dose reductions (6% vs. 0%,p = 0.26) and held doses (17% vs. 14%,p = 0.79) were not different between concurrent and sequential/no azole. There were no differences in the rates of new fungal infection during induction between the two groups.Azoles given concurrently or sequentially with midostaurin were found to be equally safe and effective in the treatment of newly diagnosed FLT3 AML. Additional confirmatory studies are needed due to our limited sample size. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
8. Long-Term Outcomes of Patients with Acute Myelogenous Leukemia Treated with Myeloablative Fractionated Total Body Irradiation TBI-Based Conditioning with a Tacrolimus- and Sirolimus-Based Graft-versus-Host Disease Prophylaxis Regimen: 6-Year Follow-Up from a Single Center
- Author
-
Salhotra, Amandeep, Hui, Susanta, Yang, Dongyun, Mokhtari, Sally, Mei, Matthew, Al Malki, Monzr M., Aldoss, Ibrahim, Ali, Haris, Sandhu, Karamjeet S., Aribi, Ahmed, Khaled, Samer, Dandapani, Savita, Peng, Kelly, Teh, Jennifer Berano, Murata-Collins, Joyce, Budde, Elizabeth, Dadwal, Sanjeet, Pullarkat, Vinod, Snyder, David, and Spielberger, Ricardo
- Subjects
- *
BUSULFAN , *ACUTE myeloid leukemia , *TOTAL body irradiation , *GRAFT versus host disease , *MEDICAL registries , *HEPATIC veno-occlusive disease , *ALEMTUZUMAB , *CELL transplantation - Abstract
• Fractionated total body irradiation-based myeloablative conditioning is well tolerated in young adults with acute myelogenous leukemia. • Tacrolimus/sirolimus graft-versus-host disease (GVHD) prophylaxis was associated with high rates of chronic GVHD (71%). • GVHD-free, relapse free survival at 2 years was low (39%), indicating the dynamic nature of chronic GVHD. • This regimen was associated with a low risk of long-term toxicities. Cyclophosphamide (Cy)/etoposide combined with fractionated total body irradiation (FTBI) or i.v. busulfan (Bu) has been the main conditioning regimens for allogeneic hematopoietic cell transplantation (alloHCT) for young patients with acute myelogenous leukemia (AML) eligible for a myeloablative conditioning (MAC) regimen. Recent data has suggested that i.v. Bu could be the preferred myeloablative regimen in patients with myeloid malignancies. However, Bu-based regimens are associated with higher rates of sinusoidal obstruction syndrome. Here we report long-term survival outcomes of patients with AML receiving FTBI combined with Cy or etoposide before undergoing alloHCT at City of Hope (COH). We obtained a retrospective review of a prospectively maintained institutional registry of clinical outcomes in 167 patients (median age, 41 years; range, 18 to 57 years) with AML in first or second complete remission who underwent alloHCT at COH between 2005 and 2015. Eligible patients received a MAC regimen with FTBI (1320 cGy) and Cy (120 mg/kg) for unrelated donor transplantation or etoposide (60 mg/kg) for related donor transplantation. Graft-versus-host disease (GVHD) prophylaxis was provided with tacrolimus and sirolimus. In this retrospective study, 6-year overall survival was 60% and nonrelapse mortality was 15%. The GRFS rate was 45% at 1 year and 39% at 2 years. We also describe late metabolic effects and report the cumulative incidence of secondary malignancies (9.5%). Overall, in this young adult patient population, our results compare favorably to chemotherapy-based (i.v. Bu) conditioning regimens without significant long-term toxicity arising from TBI-based regimens. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
9. Melphalan-Based Reduced-Intensity Conditioning is Associated with Favorable Disease Control and Acceptable Toxicities in Patients Older Than 70 with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
- Author
-
Al Malki, Monzr M., Nathwani, Nitya, Yang, Dongyun, Armenian, Saro, Dadwal, Sanjeet, Salman, Jaroslava, Mokhtari, Sally, Cao, Thai, Sandhu, Karamjeet, Rouse, Michelle, Mei, Matthew, Ali, Haris, Parker, Pablo, Alvarnas, Joseph, Smith, Eileen, Donnell, Margaret O., Marcucci, Guido, Snyder, David, Nademanee, Auayporn, and Forman, Stephen J.
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *MELPHALAN , *HEMATOLOGIC malignancies , *GRAFT versus host disease , *NEUTROPHILS , *ACUTE myeloid leukemia , *OLDER patients , *PROGRESSION-free survival , *PATIENTS - Abstract
Highlights • Semiablative melphalan-based conditioning regimen is safe for eligible elderly patients. • Rapid hematopoietic reconstitution after this regimen led to favorable survival outcomes. • Morbidity indicators (infection, etc.) were similar to younger patients undergoing same regimen. • This regimen is effective with promising relapse rate and minimal toxicities for patients > 70. Abstract Allogeneic hematopoietic stem cell transplantation (alloHCT) is offered increasingly to elderly patients with hematologic malignancies. However, outcome data in those who are 70 years or older are limited, and no standard conditioning regimen has been established for this population. In this retrospective study we evaluated the outcome of 53 consecutive patients aged 70 years and older who underwent alloHCT with melphalan-based reduced-intensity conditioning (RIC) at City of Hope. Engraftment was prompt, with median time to neutrophil engraftment of 15 days. More than 95% of patients achieved complete donor chimerism within 6 weeks from HCT, consistent with the "semiablative" nature of this regimen. With a median follow-up of 31.1 months, the 2-year overall survival (OS), progression-free survival (PFS), and nonrelapse mortality (NRM) were 68.9%, 63.8%, and 17.0%, respectively. Cumulative incidence of relapse at 1 and 2 years was 17.0% and 19.3%, respectively. One hundred–day cumulative incidence of grades II to IV acute graft-versus-host disease was 37.7% (grades III to IV, 18.9%), and 2-year cumulative incidence of chronic graft-versus-host disease was 61.9% (extensive, 45.9%). The only significant predictor for poor OS was high/very high disease risk index. Transplant-related complications and morbidities observed here did not differ from the commonly expected in younger patients treated with RIC. In conclusion, alloHCT with a melphalan-based conditioning regimen is associated with acceptable toxicities and NRM, lower incidence of relapse, and favorable OS and PFS in patients aged 70 years or older. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.